IMMY - Imprimis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.69
+0.50 (+9.63%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.19
Open5.25
Bid0.00 x 800
Ask0.00 x 800
Day's Range5.25 - 5.82
52 Week Range1.45 - 6.50
Volume377,513
Avg. Volume474,479
Market Cap132.452M
Beta (3Y Monthly)-0.50
PE Ratio (TTM)N/A
EPS (TTM)-0.30
Earnings DateMar 6, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.75
Trade prices are not sourced from all markets
  • Best Sector of 2018 and its Hit ETFs & Stocks
    Zacks19 days ago

    Best Sector of 2018 and its Hit ETFs & Stocks

    Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.

  • GlobeNewswire21 days ago

    Imprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc.

    Mark L. Baum, CEO of Harrow Health, stated, “Our new name reflects our business model of creating, investing in, operating and growing a diversified portfolio of healthcare businesses that meet the needs of healthcare providers and patients across America. Harrow Health’s businesses and subsidiaries each have strong brand equity and will continue to operate under the Harrow Health corporate umbrella using their existing names. This includes Harrow Health’s wholly-owned subsidiaries ImprimisRx, the nation’s leading ophthalmology pharmaceutical compounding business, and Park Compounding.

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE2 months ago

    4 Healthcare Stocks Taking a New Approach to Growth Trends

    CORAL GABLES, FL / ACCESSWIRE / November 19, 2018 / Healthcare stocks have rallied during the last 3 trading sessions. On Friday, the market powered higher, lead by healthcare stocks. Furthermore, the idea that a split congress could be a good thing for healthcare stocks is offering a brighter outlook for some investors to look closer at several smaller healthcare companies that could be set to rebound.

  • ACCESSWIRE2 months ago

    4 Healthcare Stocks Investors Should Get Familiar With

    CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / The healthcare sector is the sector of the economy made up of companies that specialize in products and services related to health and medical care. As the industry continues to emerge as a leading place for investors to hedge against broader market volatility, companies like Premier Health Group, Inc. (PHGRF) (PHGI), ReShape Lifesciences Inc. (RSLS), Teladoc (TDOC), and Imprimis Pharmaceuticals, Inc. (IMMY). Premier Health Group, Inc. (PHGRF) (PHGI) is focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry.

  • Associated Press2 months ago

    Imprimis: 3Q Earnings Snapshot

    The San Diego-based company said it had a loss of 12 cents per share. The pharmaceutical and drug compounding company posted revenue of $10.7 million in the period. In the final minutes of trading on Tuesday, ...

  • GlobeNewswire2 months ago

    Imprimis Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 13, 2018

    Imprimis Pharmaceuticals, Inc. (IMMY) today announced it will release third quarter 2018 financial results after the close of trading on Tuesday, November 13, 2018.  The company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day to discuss the financial results and recent business developments. Imprimis Pharmaceuticals, Inc. (IMMY) is a commercial-stage pharmaceutical company based in San Diego, California.  In addition to owning the nation’s leading ophthalmology pharmaceutical compounding business, ImprimisRx, the Company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals and Melt Pharmaceuticals, companies originally founded as subsidiaries of Imprimis.  The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface and Melt.  For more information about Imprimis, please visit the Investor Relations section of the corporate website by clicking here.

  • InvestorPlace3 months ago

    10 Small-Caps With Straight-A Potential

    Since the financial collapse, the Federal Reserve — and then other nations’ central banks — took off monetary policy to make sure there wasn’t a massive global financial collapse. Interest rates are rising again and now portfolio managers are reallocating assets across stocks and bonds. Imprimis Pharmaceuticals (NASDAQ:IMMY) is a San Diego-based pharmaceutical company that specializes in compounded pharmaceuticals.

  • Associated Press6 months ago

    Imprimis: 2Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had net income of 12 cents. The pharmaceutical and drug compounding company posted revenue of $10.4 million in the period. In the final minutes ...

  • Imprimis Pharmaceuticals Announces Second Quarter 2018 Results
    PR Newswire6 months ago

    Imprimis Pharmaceuticals Announces Second Quarter 2018 Results

    SAN DIEGO , Aug. 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the second quarter 2018. Notable Highlights from the Second Quarter of 2018: Revenues of ...

  • ACCESSWIRE6 months ago

    Imprimis Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern ...

  • Imprimis Announces Multi-Center Clinical Trial for Dropless® TriMoxi™ (Triamcinolone Acetonide-Moxifloxacin for injection) Formulation in Canada
    PR Newswire6 months ago

    Imprimis Announces Multi-Center Clinical Trial for Dropless® TriMoxi™ (Triamcinolone Acetonide-Moxifloxacin for injection) Formulation in Canada

    Study to assess drug safety, patient preference and pharmacoeconomic measures in 200 routine cataract surgeries SAN DIEGO , Aug. 1, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) through ...

  • Imprimis Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference on August 9, 2018
    PR Newswire6 months ago

    Imprimis Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference on August 9, 2018

    SAN DIEGO , July 18, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum ...

  • ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery
    PR Newswire8 months ago

    ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery

    SAN DIEGO, May 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.'s (IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study published in the Journal of Cataract and Refractive Surgery in January 2018, which followed 483 eyes with glaucoma that were undergoing cataract surgery with concomitant trabecular microbypass stent insertion.  The study was initially presented at the American Society of Cataract and Refractive Surgery (ASCRS) and examines post-surgery outcomes for patients receiving an intravitreal injection of steroid and antibiotics at the time of surgery compared with a standard drop regimen following surgery. All study participants were diagnosed with primary open-angle glaucoma and received a glaucoma stent at the time of surgery in parallel with the cataract surgery procedure.  The study group of 234 eyes received an intravitreal injection (pars plana) of 0.2 mL of Dropless®, a combination of steroid and antibiotics, at the time of surgery.  The control group of 249 eyes received a standard topical regimen postoperatively.

  • ACCESSWIRE8 months ago

    Blog Exposure - Emergent BioSolutions and Profectus BioSciences Receive Contract from CEPI to Develop Nipah Virus Vaccine

    LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EBS as the Company's latest news hit the wire. On May 24, 2018, the Company announced that the Coalition for Epidemic Preparedness Innovations (CEPI) has provided up to $25 million to the Company and Profectus BioSciences, Inc. ("Profectus") to advance the development and manufacture of a vaccine against the Nipah virus (NiV), a bat-borne virus that can spread to both humans and livestock. Active-Investors.com is currently working on the research report for Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which also belongs to the Healthcare sector as the Company Emergent BioSolutions.

  • Imprimis Pharmaceuticals Announces First Quarter 2018 Results
    PR Newswire8 months ago

    Imprimis Pharmaceuticals Announces First Quarter 2018 Results

    SAN DIEGO, May 15, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY) today reported financial results for the first quarter 2018. Imprimis Pharmaceuticals has retained ownership of 3.5 million shares of Eton Pharmaceuticals common stock and 3.5 million shares of Surface Pharmaceuticals common stock.  In addition, Imprimis owns mid-single digit royalty rights on all contributed drugs.  Imprimis retains royalty rights on two patent-pending sterile injectable drug candidates contributed to Eton, one targeting infantile spasms and the other targeting Peyronie's Disease.  Imprimis retains royalty rights on three patent-pending drug candidates contributed to Surface, two are topical eye drop drug candidates, the third is an oral capsule, all of which target certain ocular surface diseases.

  • Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners
    PR Newswire8 months ago

    Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners

    SAN DIEGO, and PLEASANTON, Calif., May 15, 2018 /PRNewswire/ -- Surface Pharmaceuticals, Inc., an affiliated company of Imprimis Pharmaceuticals, Inc. (IMMY), today announced it has entered into a definitive stock purchase agreement with an affiliate of Flying L Partners to raise proceeds of up to approximately $20 million in a private placement of its Series A preferred stock.  Surface Pharmaceuticals intends to use the proceeds of the Series A financing to advance its clinical development programs focused on ocular surface disease, including Dry Eye Disease treatments, by seeking FDA approval for three drug candidates for up to five indications, as well as for general corporate purposes.